PTC Therapeutics, Inc. Operating Lease Cost
PTC Therapeutics, Inc. (PTCT) reported Operating Lease Cost of $14.69 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-19
- PTC Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $3.85M, a 5.99% decline year-over-year.
- PTC Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $4.03M, a 0.42% decline year-over-year.
- PTC Therapeutics, Inc. operating lease, cost for the quarter ending 2025-06-30 was $3.44M, a 37.97% decline year-over-year.
- PTC Therapeutics, Inc. operating lease, cost for the quarter ending 2025-03-31 was $3.37M, a 39.52% decline year-over-year.
- PTC Therapeutics, Inc. operating lease, cost for fiscal 2025 was $14.69M, a 23.73% decline from fiscal 2024.
- PTC Therapeutics, Inc. operating lease, cost for fiscal 2024 was $19.26M, a 12.24% decline from fiscal 2023.
- PTC Therapeutics, Inc. operating lease, cost for fiscal 2023 was $21.95M, a 10.85% increase from fiscal 2022.
- PTC Therapeutics, Inc. operating lease, cost for fiscal 2022 was $19.80M, a 20.68% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $7.88M derived: sum of 2 quarters · filed 2026-02-19 | $11.32M derived: sum of 3 quarters · filed 2026-02-19 | $14.69M 10-K · filed 2026-02-19 | |
| 2025-09-30 | $4.03M 10-Q · filed 2025-11-04 | $7.47M derived: sum of 2 quarters · filed 2025-11-04 | $10.85M 10-Q · filed 2025-11-04 | $14.94M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2025-06-30 | $3.44M 10-Q · filed 2025-08-07 | $6.81M 10-Q · filed 2025-08-07 | $10.90M derived: sum of 3 quarters · filed 2026-02-19 | $14.95M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2025-03-31 | $3.37M 10-Q · filed 2025-05-06 | $7.46M derived: sum of 2 quarters · filed 2026-02-19 | $11.51M derived: sum of 3 quarters · filed 2026-02-19 | $17.06M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-12-31 | $4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $8.14M derived: sum of 2 quarters · filed 2026-02-19 | $13.69M derived: sum of 3 quarters · filed 2026-02-19 | $19.26M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $4.05M 10-Q · filed 2025-11-04 | $9.60M derived: sum of 2 quarters · filed 2025-11-04 | $15.17M 10-Q · filed 2025-11-04 | $20.66M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-06-30 | $5.55M 10-Q · filed 2025-08-07 | $11.12M 10-Q · filed 2025-08-07 | $16.61M derived: sum of 3 quarters · filed 2026-02-19 | $22.10M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-03-31 | $5.58M 10-Q · filed 2025-05-06 | $11.06M derived: sum of 2 quarters · filed 2026-02-19 | $16.55M derived: sum of 3 quarters · filed 2026-02-19 | $22.05M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2023-12-31 | $5.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $10.98M derived: sum of 2 quarters · filed 2026-02-19 | $16.48M derived: sum of 3 quarters · filed 2026-02-19 | $21.95M 10-K · filed 2026-02-19 | |
| 2023-09-30 | $5.49M 10-Q · filed 2024-11-07 | $10.99M derived: sum of 2 quarters · filed 2024-11-07 | $16.46M 10-Q · filed 2024-11-07 | $22.00M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $5.50M 10-Q · filed 2024-08-08 | $10.97M 10-Q · filed 2024-08-08 | $16.51M derived: sum of 3 quarters · filed 2025-02-27 | $21.89M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $5.47M 10-Q · filed 2024-04-25 | $11.01M derived: sum of 2 quarters · filed 2025-02-27 | $16.39M derived: sum of 3 quarters · filed 2025-02-27 | $21.15M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $5.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $10.91M derived: sum of 2 quarters · filed 2025-02-27 | $15.68M derived: sum of 3 quarters · filed 2025-02-27 | $19.80M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $5.38M 10-Q · filed 2023-10-26 | $10.14M derived: sum of 2 quarters · filed 2023-10-26 | $14.27M 10-Q · filed 2023-10-26 | $18.40M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $4.76M 10-Q · filed 2023-08-03 | $8.89M 10-Q · filed 2023-08-03 | $13.02M derived: sum of 3 quarters · filed 2024-02-29 | $17.08M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $4.13M 10-Q · filed 2023-04-27 | $8.26M derived: sum of 2 quarters · filed 2024-02-29 | $12.32M derived: sum of 3 quarters · filed 2024-02-29 | $16.43M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $8.19M derived: sum of 2 quarters · filed 2024-02-29 | $12.31M derived: sum of 3 quarters · filed 2024-02-29 | $16.41M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $4.06M 10-Q · filed 2022-10-27 | $8.17M derived: sum of 2 quarters · filed 2022-10-27 | $12.28M 10-Q · filed 2022-10-27 | $12.37B derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-06-30 | $4.12M 10-Q · filed 2022-08-04 | $8.22M 10-Q · filed 2022-08-04 | $12.37B derived: sum of 3 quarters · filed 2023-02-21 | $12.37B derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-03-31 | $4.10M 10-Q · filed 2022-05-03 | $12.36B derived: sum of 2 quarters · filed 2023-02-21 | $12.37B derived: sum of 3 quarters · filed 2023-02-21 | $12.37B derived: sum of 4 quarters · filed 2023-02-21 | |
| 2020-12-31 | $12.36B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $12.36B derived: sum of 2 quarters · filed 2023-02-21 | $12.37B derived: sum of 3 quarters · filed 2023-02-21 | $12.37B 10-K · filed 2023-02-21 | $12.37M 10-K · filed 2021-02-25 |
| 2020-09-30 | $4.10M 10-Q · filed 2021-10-28 | $6.07M derived: sum of 2 quarters · filed 2021-10-28 | $7.90M 10-Q · filed 2021-10-28 | $4.93B derived: sum of 4 quarters · filed 2022-02-22 | |
| 2020-06-30 | $1.97M 10-Q · filed 2021-07-29 | $4.09M 10-Q · filed 2021-07-29 | $4.93B derived: sum of 3 quarters · filed 2022-02-22 | $4.93B derived: sum of 4 quarters · filed 2022-02-22 | |
| 2020-03-31 | $2.12M 10-Q · filed 2021-05-04 | $4.93B derived: sum of 2 quarters · filed 2022-02-22 | $4.93B derived: sum of 3 quarters · filed 2022-02-22 | $4.93B derived: sum of 4 quarters · filed 2022-02-22 | |
| 2019-12-31 | $4.93B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $4.93B derived: sum of 2 quarters · filed 2022-02-22 | $4.93B derived: sum of 3 quarters · filed 2022-02-22 | $4.93B 10-K · filed 2022-02-22 | $4.93M 10-K · filed 2020-03-02 |
| 2019-09-30 | $1.43M 10-Q · filed 2020-10-29 | $2.27M derived: sum of 2 quarters · filed 2020-10-29 | $3.08M 10-Q · filed 2020-10-29 | ||
| 2019-06-30 | $835.00K 10-Q · filed 2020-08-05 | $1.65M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $812.00K 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |